The stock's fall snapped a two-day winning streak.

Shares of Biogen Inc. BIIB slid 1.10% to $142.34 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...

In a report released today, David Amsellem from Piper Sandler maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report), with ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen Pharmachem Industries Ltd share price was down by -0.86% from the previous closing price of ₹1.16. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...

The "Strategic Intelligence: Orphan Designated Drugs" report has been added to ResearchAndMarkets.com's offering.This report consolidates the latest thinking and forecasts around how the healthcare, ...